HCM
CRBP icon

Highbridge Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Highbridge Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-659
Closed -$141K – 1682
2017
Q3 		$141K Sell
659
-1,798
-73% -$352K ﹤0.01% 1455
2017
Q2 		$464K Hold
2,457
– – 0.01% 778
2017
Q1 		$608K Buy
2,457
+682
+38% +$167K 0.01% 813
2016
Q4 		$450K Buy
+1,775
New +$407K 0.01% 806

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highbridge Capital Management's CRBP Position: Q4 2017 in Review

Highbridge Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2017, closing a stake of 659 shares — an estimated $141K sold.

Highbridge Capital Management first reported a position in CRBP in Q4 2016 and held it in 4 quarters. The position peaked at $608K in Q1 2017. 88 funds tracked by Wall St. Rank hold CRBP as of Q4 2017.

  • Highbridge Capital Management reported no remaining Corbus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 659 Corbus Pharmaceuticals shares in Q4 2017, an estimated $141K.
  • Highbridge Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Highbridge Capital Management's Corbus Pharmaceuticals position peaked at $608K in Q1 2017.
  • 88 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.